ストックスクリーナーアプリを入手
34.90
3.81%
1.28
前日終値:
$33.62
開ける：
$33.54
24時間の取引高:
16.22M
Relative Volume:
0.58
時価総額：
$7.65B
収益：
$1.78B
当期純損益:
$164.40M
株価収益率:
50.58
EPS:
0.69
ネットキャッシュフロー:
$236.51M
1週間 パフォーマンス:
-5.62%
1か月 パフォーマンス:
-29.29%
6か月 パフォーマンス:
-39.83%
1年 パフォーマンス:
+44.51%
1日の値動き範囲:
$32.88
$34.99
1週間の範囲:
$32.88
$37.63
52週間の値動き範囲:
$23.03
$72.98
Hims Hers Health Inc Stock (HIMS) Company Profile
HIMS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
34.88 | 7.65B | 1.78B | 164.40M | 236.51M | 0.69 |
|
ZTS
Zoetis Inc
|
121.96 | 51.07B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.33 | 44.42B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.865 | 42.75B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.21 | 27.86B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
475.43 | 20.44B | 3.08B | 1.24B | 1.07B | 25.61 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-21 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | ダウングレード | Needham | Buy → Hold |
| 2025-06-04 | 繰り返されました | Needham | Buy |
| 2025-04-29 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-02-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | ダウングレード | Citigroup | Neutral → Sell |
| 2025-01-07 | 開始されました | BTIG Research | Buy |
| 2024-12-17 | 開始されました | Morgan Stanley | Overweight |
| 2024-11-14 | ダウングレード | BofA Securities | Buy → Underperform |
| 2024-08-22 | 開始されました | Needham | Buy |
| 2024-08-09 | ダウングレード | Imperial Capital | Outperform → In-line |
| 2024-05-22 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-04-16 | ダウングレード | Jefferies | Buy → Hold |
| 2024-04-10 | 開始されました | Canaccord Genuity | Buy |
| 2024-02-28 | アップグレード | Imperial Capital | In-line → Outperform |
| 2024-02-26 | 開始されました | Leerink Partners | Market Perform |
| 2023-12-07 | 開始されました | Imperial Capital | In-line |
| 2023-07-28 | 開始されました | TD Cowen | Outperform |
| 2023-04-11 | 開始されました | Robert W. Baird | Neutral |
| 2023-02-09 | アップグレード | Jefferies | Hold → Buy |
| 2022-11-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-11-08 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | 開始されました | Truist | Hold |
| 2022-07-15 | 開始されました | SVB Leerink | Underperform |
| 2022-04-14 | 開始されました | Guggenheim | Buy |
| 2022-04-01 | 再開されました | Credit Suisse | Outperform |
| 2022-03-10 | 開始されました | Deutsche Bank | Hold |
| 2021-12-02 | 開始されました | Jefferies | Hold |
| 2021-11-11 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | 開始されました | BofA Securities | Neutral |
| 2021-05-20 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | 開始されました | Truist | Hold |
| 2021-03-09 | 開始されました | Credit Suisse | Neutral |
| 2021-03-02 | アップグレード | Citigroup | Neutral → Buy |
| 2021-02-17 | 開始されました | Citigroup | Neutral |
| 2021-02-12 | 開始されました | Piper Sandler | Neutral |
| 2021-02-08 | 開始されました | Tigress Financial | Buy |
すべてを表示
Hims Hers Health Inc (HIMS) 最新ニュース
How Novo Nordisk Is Trying to Regain Its Weight-Loss Edge - Bloomberg.com
Hims & Hers Accelerates Its Clinician-Led, Platform-Driven Care Model - Yahoo Finance
Hims & Hers Health Options Trading: A Deep Dive into Market Sentiment - Benzinga
OMCL or HIMS: Which Is the Better Value Stock Right Now? - sharewise.com
Hims & Hers Health: A Notable Shift Toward Core - Smartkarma
HIMS Has Been a Roller Coaster Ride. Should Investors Hop On? - MarketBeat
Hims & Hers Health Insider Sold Shares Worth $853,490, According to a Recent SEC Filing - MarketScreener
Hims & Hers Health Stock (HIMS) Opinions on Q3 Earnings and Competitive Challenges - Quiver Quantitative
Hers Health Inc. stock surprise with earnings upside2025 Geopolitical Influence & Weekly Breakout Watchlists - newser.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: NRX Pharmaceuticals (NRXP), LifeMD (LFMD) and Hims & Hers Health (HIMS) - The Globe and Mail
Parents Sue Hims After Washington State Student’s Suicide - USA Herald
Hims & Hers Plunges 15.6% in 3 Months: Time to Hold the Stock or Sell? - TradingView
Commit To Purchase Hims & Hers Health At $20, Earn 27.2% Using Options - Nasdaq
Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now? - Yahoo Finance
The Price Is Right For Hims & Hers Health, Inc. (NYSE:HIMS) Even After Diving 29% - simplywall.st
Telehealth Co. Hims Sued Over College Student's Suicide - Law360
Key facts: Hims & Hers shares fall 4.9%; Deb Autor appointed Chief Policy Officer - TradingView
Why Hims & Hers Health (HIMS) Shares Are Trading Lower Today - Finviz
What's Going On With Hims & Hers Health Shares Monday? - Benzinga
Hims & Hers Health board approves $250 million share repurchase program - Investing.com Nigeria
Hims & Hers Health stock rises after announcing $250 million buyback program - MSN
Hims & Hers names ex-FDA official Deb Autor as first policy chief - Reuters
Hims & Hers health authorizes $250 million share repurchase program - MSN
Hims & Hers Health, Inc. Appoints Deb Autor as the First Chief Policy Officer - MarketScreener
Hims & Hers Announces New $250 Million Share Repurchase Program – Retail Sees A Steady Trading Range For The Stock - Stocktwits
Hims & Hers Health effects new up to $250M stock buyback program, shares up ~2% - MSN
Hims & Hers Health Announces New Share Buyback Program - TipRanks
Hims & Hers Health effects new up to $250M stock buyback program, shares up ~2% (HIMS:NYSE) - Seeking Alpha
Hims & Hers announces $250 million share repurchase program - Investing.com India
Hims & Hers Health Announces New Share Repurchase Program - TradingView
Hims & Hers Health, Inc. Announces $250 Million Share Repurchase Program Authorization - Hims Investor Relations
Hims & Hers appoints former FDA leader Deb Autor as first CPO - Investing.com Canada
Hims & Hers Names Deb Autor as Chief Policy Officer to Lead Global Policy and Regulatory Strategy - The AI Journal
Hims & Hers appoints former FDA leader Deb Autor as first CPO By Investing.com - Investing.com South Africa
Why I’m Joining Hims & Hers - Hims & Hers Newsroom
Hims & Hers Launches ‘Labs’ to Expand Into Data-Driven Diagnostics - Global Cosmetics News
Hims & Hers Health’s Valuation in Focus After Wrongful Death Lawsuit Raises New Questions - Yahoo Finance
Hims & Hers Enters Direct-to-Consumer Lab Testing %%sep%% %%sitename%% - Newsweek
Hims & Hers Introduces Labs With Annual Plans For Comprehensive Testing - Benzinga
Family Alleges Hims & Hers Health, Inc.’s Rush Into Mental Healthcare Violated Washington Law and Resulted in Son’s Death - The Manila Times
Family Alleges Hims & Hers Health, Inc.’s Rush Into Mental - GlobeNewswire
Hims & Hers Health Stock (HIMS) Opinions on Q3 Earnings and New Platform Launch - Quiver Quantitative
Why Hims & Hers Health Shares Are Sliding - TipRanks
1 Healthcare Stock to Consider Right Now and 2 Facing Headwinds - Finviz
Hims & Hers Stock Logs 3-Day Losing Streak As Truist Calls Out Klarna GLP-1 Changes — Retail Sees Fresh Buy Zone - Stocktwits
Hims & Hers Stock Plunge: Expansion Fails to Impress Investors - AD HOC NEWS
Hims & Hers Bets on Lab Testing to Boost Growth - The Wall Street Journal
Health Care Flat as Traders Rotate Into Sectors Less Dependent on AI Boom -- Health Care Roundup - MarketWatch
Family of WSU student files wrongful death lawsuit against Hims & Hers over antidepressant prescription - NonStop Local KHQ
Family of WSU student who died by suicide in 2023 sues Hims & Hers Health, Theta Chi fraternity for wrongful death - KREM
Key facts: Hims & Hers Health expands telehealth services; Officer sells shares - TradingView
Hims Hers Health Inc (HIMS) 財務データ
収益
当期純利益
現金流量
EPS
4.50%
0.15%
大文字化:
|
ボリューム (24 時間):